911
Views
0
CrossRef citations to date
0
Altmetric
Vaccine Safety

Effectiveness of Enterovirus 71 inactivated vaccines against hand, foot, and mouth disease: A test-negative case-control study

, , , , , , , & show all
Article: 2330163 | Received 15 Dec 2023, Accepted 10 Mar 2024, Published online: 27 Mar 2024

References

  • Zhang W, Huang Z, Huang M, Zeng J. Predicting severe enterovirus 71-infected hand, foot, and mouth disease: Cytokines and Chemokines. Mediators Inflamm. 2020;2020:1–6. doi:10.1155/2020/9273241.
  • Cui J, Nei T, Ren M, Liu FF, Li Y, Wang LP, Tan JB, Chang ZR, Li ZJ. Epidemiological characteristics of fatal cases of hand, foot, and mouth disease in children under 5 years old in China, 2008–2018. Chin J Epidemiol. 2020;41(7):1041–1046. (in Chinese). doi:10.3760/cma.j.cn112338-20200114-00031.
  • Cox JA, Hiscox JA, Solomon T, Ooi M-H, Ng LFP. Immunopathogenesis and virus–host interactions of enterovirus 71 in patients with hand, foot and mouth disease. Front Microbiol. 2017;8:2249. doi:10.3389/fmicb.2017.02249.
  • Ren M, Cui J, Nie T, Liu FF, Sun JL, Zhang YW, Chang ZR. Epidemiological characteristics of severe cases of hand, foot, and mouth disease in China, 2008–2018. Chin J Epidemiol. 2020;41(11):1802–1807. (in Chinese). doi:10.3760/cma.j.cn112338-20200201-00063.
  • Koh WM, Badaruddin H, La H, Chen MIC, Cook AR. Severity and burden of hand, foot and mouth disease in Asia: a modelling study. BMJ Glob Health. 2018;3(1):e000442. doi:10.1136/bmjgh-2017-000442.
  • Nhan L, Turner HC, Khanh TH, Hung NT, Lien LB, Hong NTT, Nhu LNT, Ny NTH, Nguyet LA, Thanh TT, et al. Economic burden attributed to children presenting to hospitals with hand, foot, and mouth disease in Vietnam. Open Forum Infect Dis. 2019;6(7). doi:10.1093/ofid/ofz284.
  • Zheng Y, Jit M, Wu JT, Yang J, Leung K, Liao Q, Yu H. Economic costs and health-related quality of life for hand, foot and mouth disease (HFMD) patients in China. PLoS One. 2017;12(9):e0184266. doi:10.1371/journal.pone.0184266.
  • Wei MW, Meng FY, Wang SY, Li J, Zhang Y, Mao Q, Hu Y, Liu P, Shi N, Tao H, et al. 2-year efficacy, immunogenicity, and safety of vigoo enterovirus 71 vaccine in healthy Chinese children: a randomized open-label study. J Infect Dis. 2017;215(1):56–63. doi:10.1093/infdis/jiw502.
  • Bello AM, Roshorm YM. Recent progress and advances towards developing enterovirus 71 vaccines for effective protection against human hand, foot and mouth disease (HFMD). Biologicals. 2022;79:1–9. doi:10.1016/j.biologicals.2022.08.007.
  • Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–828. doi:10.1056/NEJMoa1304923.
  • Zhang L, Li Y, Wang L, Xu L, Li KL, Zeng G, An ZJ. Validation of a test-negative design case-control study for evaluating the effectiveness of enterovirus 71 inactivated vaccine. Chin J Vaccines Immun.2022;28(1):41–45. (in Chinese)
  • Wang X, An Z, Huo D, Jia L, Li J, Yang Y, Liang Z, Wang Q, Wang H. Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China. Hum Vaccines Immunother. 2019;15(5):1183–1190. doi:10.1080/21645515.2019.1581539.
  • Li Y, Zhou Y, Cheng Y, Wu P, Zhou C, Cui P, Song C, Liang L, Wang F, Qiu Q, et al. Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017–18: a test-negative case-control study. Lancet Child Adolesc Health. 2019;3(10):697–704. doi:10.1016/S2352-4642(19)30185-3.
  • Jiang L, Wang J, Zhang C, He W, Mo J, Zeng J, Chen M, Tan Y, Ning C. Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth disease cases in Guangxi, China. Vaccine. 2020;38(7):1804–1809. doi:10.1016/j.vaccine.2019.12.025.
  • Zhang L, Cao L, Li Y, Hu YX, Tang L, Li KL, Yin ZD, An ZJ. Analysis of the vaccination status of enterovirus type 71 inactivated vaccine in China from 2017 to 2021. Chin J Epidemiol. 2023;44(4):561–567. (in Chinese). doi:10.3760/cma.j.cn112338-20220811-00704.
  • National Health Commission of the People’s Republic of China. Hand-foot-and-mouth disease treatment guide (2018 edition). Infect Dis Inf. 2018;31(3):193–198. (in Chinese)
  • Yang B, Liu F, Liao Q, Wu P, Chang Z, Huang J, Long L, Luo L, Li Y, Leung GM, et al. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro Surveill. 2017;22(50). doi:10.2807/1560-7917.ES.2017.22.50.16-00824.
  • Li J, Pan H, Wang X, Zhu Q, Ge Y, Cai J, Li Y, Xia A, Hu J, Zeng M. Epidemiological surveillance of hand, foot and mouth disease in Shanghai in 2014–2016, prior to the introduction of the enterovirus 71 vaccine. Emerg Microbes Infect. 2018;7(1):1–7. doi:10.1038/s41426-018-0035-z.
  • Zhu FC, Meng FY, Li JX, Li X-L, Mao Q-Y, Tao H, Zhang Y-T, Yao X, Chu K, Chen Q-H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2013;381(9882):2024–2032. doi:10.1016/S0140-6736(13)61049-1.
  • Tao Y, Jin P, Zhu F. Meta-analysis on effectiveness of live attenuated influenza vaccine against seasonal influenza in children. Chin J Epidemiol. 2020;41(1):103–110. (in Chinese). doi:10.3760/cma.j.issn.0254-6450.2020.01.019.
  • Gu W, Zeng G, Hu YM, Hu Y-S, Zhang Y, Hu Y-L, Wang Y, Li J-X, Zhu F-C. A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3–5 years and infants aged 6–35 months. Expert Rev Vaccines. 2018;17(3):257–262. doi:10.1080/14760584.2018.1430572.
  • Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert Rev Vaccines. 2014;13(12):1571–1591. doi:10.1586/14760584.2014.966695.